Navigation Links
Genmab Announces Year End 2007 Financial Results
Date:3/31/2008

three milestones in Roche collaboration

Gained rights to HuMax-CD4 and HuMax-TAC from Merck Serono and HuMax-IL8

through asset exchange with Medarex

Commenced seven new studies:

HuMax-EGFr - Phase III front line head and neck cancer study by DAHANCA

and Phase II non small cell lung cancer study

HuMax-CD20 - Phase II front line CHOP combination study in follicular

non-Hodgkin's lymphoma, 2 RA Phase III studies, Phase II relapsed

diffuse large B-cell lymphoma study

HuMax-CD38 Phase I/II multiple myeloma study

Achieved positive clinical trial results:

HuMax-CD20 Phase II RA data

Final HuMax-CD4 Phase II cutaneous T-cell lymphoma (CTCL) data

R1507 Phase I sarcoma data

Presented pre-clinical data:

Positive data for HuMax-HepC, HuMax-EGFr and HuMax-CD20

Unique mechanisms of action of HuMax-CD4 and HuMax-EGFr

Financial Highlights:

Cash position increased for fourth consecutive year

Achieved membership in OMXC20 index on the OMX Nordic Exchange

Copenhagen

2008 Guidance

We expect to significantly expand development in 2008 in our clinical and pre-clinical programs, including plans to initiate 17 new clinical studies, filing our first biologics license application and selecting two new clinical candidates. We will pay development costs for the new and ongoing pivotal studies in HuMax-CD4 and HuMax-EGFr. Under our collaboration with GSK, we will fund half the development costs for the trials with HuMax-CD20. We expect to continue our increasing level of discovery and pre-clinical work in 2008, developing antibody products for a variety of new and existing disease targets. Finally, the 2008 projections include operating costs from the newly acquired antibody manufacturing facility.

Due to these expanded activities, Genmab's operating costs are expected to be higher in 2008 than in 2007. In combination with increasing re
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
11. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... London, UK (PRWEB) March 01, 2015 ... a partnership agreement for quality market research promotion ... and sell research reports worked out by DataGroup ... Department at Market Publishers Ltd, commented on the ... to have DataGroup Booksellers in our team of ...
(Date:2/27/2015)...  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... newly developed Bruton,s tyrosine kinase (BTK) inhibitor for ... results of these preclinical evaluations have been communicated ... feedback received from the Agency is supportive of ... preclinical work is required to begin a Phase ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 The ... system (Nexera UC) can sequentially analyze up to ... combined with high-sensitivity detection of targets by mass ... designed to fulfill the measurement requirements of a ... food products, drug delivery and search for disease ...
(Date:2/27/2015)... South San Francisco, CA (PRWEB) February 27, 2015 ... it is joining forces on February 28 with patients ... globally to raise awareness for Rare Disease Day®. ... of rare diseases and calling attention to the special ... support community around them. , “Cytokinetics is proud to ...
Breaking Biology Technology:Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6
... Announces Revised Operating Plan to Respond to NEBIDO Delay, ... IDEV ) today announced that it has received,an ... (FDA) for,NEBIDO(R) related to a New Drug Application (NDA) ... on June 27, 2008, indicated that the,application may be ...
... Company to Commercialize ... Novel Technology from UC Davis, BOSTON, ... early stage university business ventures, has,established RF Biocidics, Inc., to ... UC Davis., The newly formed RF Biocidics, Inc. is ...
... 30 Raptor,Pharmaceuticals Corp. (OTC Bulletin Board: RPTP), ... private placement of 20 million units,constituting an aggregate ... and two-year warrants to purchase 10 million shares ... Company raised $9.3 million in,net proceeds from the ...
Cached Biology Technology:Indevus Receives Approvable Letter from FDA for NEBIDO(R) 2Indevus Receives Approvable Letter from FDA for NEBIDO(R) 3Indevus Receives Approvable Letter from FDA for NEBIDO(R) 4Indevus Receives Approvable Letter from FDA for NEBIDO(R) 5Indevus Receives Approvable Letter from FDA for NEBIDO(R) 6Indevus Receives Approvable Letter from FDA for NEBIDO(R) 7Allied Minds Launches Novel Disinfectant/Disinfestant Technology Start-up With UC Davis 2Raptor Pharmaceuticals Closes $10 Million Private Placement 2Raptor Pharmaceuticals Closes $10 Million Private Placement 3Raptor Pharmaceuticals Closes $10 Million Private Placement 4
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/10/2015)... WALTHAM, Mass., Feb. 10, 2015  Alere Inc. ... announced its financial results for the quarter ended ... Executive Officer and President of Alere said, "We ... refocussing Alere as the global leader in rapid ... closing the Alere Health divestiture in early January ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announces the ... as part of its 2015 marketing and branding initiatives ... new consumer website for Wocketwallet.com earlier this month. ... said, "Our new corporate website naturally showcases our premiere ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35
... (SACRAMENTO, Calif.) In what researchers say is the ... method to prevent West Nile virus, a UC Davis ... during and immediately after aerial sprayings in the summer ... from the California Department of Public Health found no ...
... a better understanding of these effects, researchers from the ... Laboratoire de recherche en cardiovasculaire, mtabolisme, diabtologie et nutrition ... mixed with low doses of dioxin, PCB, bisphenol A ... already been rendered obese by a high-fat diet. , ...
... have developed a new method for visualizing material defects ... led by Bert Nickel has, for the first time, ... thin-film solar cells using laser light for localized excitation ... scientific journal " Advanced Materials ". "We have developed ...
Cached Biology News:Aerial mosquito spraying study finds no immediate public health risks 2Aerial mosquito spraying study finds no immediate public health risks 3Food contaminants worsen metabolic problems in obese mice 2Organic electronics: Imaging defects in solar cells 2
... a variety of motion options - roller, ... unit. Shake, rock, roll and rotate motions!,, ... hybridization and blotting procedures requiring different settings, ... chamber uses a roller action to operate ...
... The Jouan MSC series of Class ... working conditions and certification to the ... regulation ensures that the cabinets cannot ... conditions. Natural lighting, low noise and ...
... Jouan RC Sensitive Bio (for heat-labile and ... systems respond to specific applications of molecular ... concentration of heat-labile samples. The RC systems ... cold traps and a wide selection of ...
... Minidizer is a personal desktop unit ideal for ... requirements. , Rotation speed set at 12 ... 80o C , Bottle capacity of four ... 15 ml conical ,plastic bottles , Consistent, ...
Biology Products: